Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review

Opinion statement The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear reco...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in oncology 2023-11, Vol.24 (11), p.1598-1613
Main Authors: Assi, Tarek, Ngo, Carine, Faron, Matthieu, Verret, Benjamin, Lévy, Antonin, Honoré, Charles, Hénon, Clémence, Le Péchoux, Cécile, Bahleda, Rastilav, Le Cesne, Axel
Format: Article
Language:English
Subjects:
Cancer therapies
Doxorubicin
Doxorubicin - therapeutic use
Gemcitabine
Humans
Life Sciences
Liposarcoma
Liposarcoma - drug therapy
Medicine
Medicine & Public Health
Oncology
Pathophysiology
Retrospective Studies
Sarcoma - therapy
Soft Tissue Neoplasms
Soft tissue sarcoma
Topical Collection on Sarcoma
Trabectedin - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opinion statement The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
ISSN:1527-2729
1534-6277
1534-5277
DOI:10.1007/s11864-023-01139-3